In a custom-made TMA with matched samples from primary tumor vs bone metastases IHC showed that most patients with TfR-positive primary tumors retained expression of TfR in bone metastases, and 63% of tumors that were negative would express TfR in the metastatic site (Fig 3). The gene discussed is TFRC; the disease is neoplasm.